Pluripotential Mechanisms of Cardioprotection with HMG-CoA Reductase Inhibitor Therapy

By Rosenson R.S.  

American Journal of Cardiovascular Drugs, Vol. 1, Iss. 6, 2001-06 ,pp. : 411-420

Adis International

Access to resources Recommend Favorite

Scientific Rationale for Combination of a Calcium Channel Antagonist and an HMG-CoA Reductase Inhibitor: A New Approach to Risk Factor Management

By Mason R. Preston  

Drugs, Vol. 68, Iss. 7, 2008-01 ,pp. : 885-900

Adis International

Access to resources Recommend Favorite

HMG-CoA Reductase Inhibitor (Statin) Therapy and Coronary Atherosclerosis in Japanese Subjects: Role of High-Density Lipoprotein Cholesterol

By Tani Shigemasa   Nagao Ken   Hirayama Atsushi  

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 6, 2011-12 ,pp. : 411-417

Adis International

Access to resources Recommend Favorite

Prevalence of Potentially Severe Drug-Drug Interactions in Ambulatory Patients with Dyslipidaemia Receiving HMG-CoA Reductase Inhibitor Therapy

By Bravo Alexandra E. Rätz  

Drug Safety, Vol. 28, Iss. 3, 2005-01 ,pp. : 263-275

Adis International

Access to resources Recommend Favorite

NK-104: a novel synthetic HMG-CoA reductase inhibitor

By Kajinami K.   Mabuchi H.   Saito Y.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 11, 2000-11 ,pp. : 2653-2661

Informa Healthcare

Access to resources Recommend Favorite